Bright Minds Biosciences
BMB-101 · 5-HT2C Selective Serotonin Agonist · Drug-Resistant Epilepsy
Company Overview
Bright Minds Biosciences is developing highly selective serotonin receptor agonists for neurological conditions. Their lead compound BMB-101 is a 5-HT2C selective agonist — designed for therapeutic neuroplasticity with a reduced hallucinogenic profile. Phase 2 BREAKTHROUGH study completed January 6, 2026 with positive topline results: 73.1% median reduction in absence seizures (p=0.012) for Drug-Resistant Epilepsy. Bright Minds is now advancing toward global registrational Phase 2/3 trials for absence seizures and Developmental and Epileptic Encephalopathy (DEE). A $175M equity offering closed January 9, 2026, giving the company more than $200M in cash. BMB-105 is in development for Prader-Willi Syndrome (NOVA Phase 2a study planned Q1 2026).
Pipeline
| Drug / Compound | Stage | Indication |
|---|---|---|
BMB-101 5-HT2C selective serotonin agonist | Phase 2 Complete | Drug-Resistant Epilepsy (Absence Seizures) |
BMB-105 5-HT2C selective serotonin agonist | Phase 2a | Prader-Willi Syndrome |
Key Financials
- Cash Position
- >$200M
- Burn Rate
- ~$2M/quarter
- Last Reported
- January 2026
Financial data is approximate. Always verify with official SEC filings.
Upcoming Catalysts
- 2026Global registrational Phase 2/3 trial initiation for Drug-Resistant Epilepsy (absence seizures and DEE)Clinical
- Q1 2026BMB-105 NOVA Phase 2a study initiation for Prader-Willi SyndromeClinical
Recent News
- 2026-01Bright Minds closes $175M equity offering January 9, 2026 — cash exceeds $200M
- 2026-01Bright Minds BREAKTHROUGH Phase 2: BMB-101 achieves 73.1% median reduction in absence seizures (p=0.012)
News items are manually curated from public company press releases.
External Links
Looking for psychedelic therapy?
Browse our directory of 700+ verified ketamine and psychedelic therapy clinics across 49 states. Find providers near you who offer ketamine and psychedelic-assisted therapy.
Disclaimer: This page is for informational purposes only and does not constitute investment, medical, or financial advice. Pipeline status, financial figures, and catalyst dates are approximate and based on publicly available information as of 2026-02-25. Always consult official company filings and a qualified financial advisor before making investment decisions.